<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421859</url>
  </required_header>
  <id_info>
    <org_study_id>11141902</org_study_id>
    <nct_id>NCT04421859</nct_id>
  </id_info>
  <brief_title>Augmented Reality Mobile Application for Glaucoma Education in the South Bronx</brief_title>
  <official_title>Augmented Reality Mobile Application for Glaucoma Education in the South Bronx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bronx-Lebanon Hospital Center Health Care System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EyeCU Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VISRE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bronx-Lebanon Hospital Center Health Care System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A team at the National Healthcare Group Eye Institute in Singapore have developed an&#xD;
      augmented reality mobile phone application, EyeCU, to simulate glaucoma progression and&#xD;
      enhance understanding about the disease and its course. It is a bilingual (English/Spanish)&#xD;
      application that is free-to-download on the Android and Apple app store. As eye care&#xD;
      physicians in the South Bronx, the investigators are hopeful that the findings in this study&#xD;
      can be extrapolated to our patients in the South Bronx, where poor health literacy,&#xD;
      non-adherence to glaucoma medication and poor follow-up remains a large barrier. The&#xD;
      investigators hope that by offering the simulation in both English and Spanish, the&#xD;
      investigators will not only be able to improve our patients' understanding of glaucoma, but&#xD;
      also improve glaucoma treatment adherence and assess our patient population's responsiveness&#xD;
      to augmented reality as an educational platform.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental design: Pilot cohort study&#xD;
&#xD;
      Data collection: Patient characteristics such as age, sex, ethnicity, preferred language, zip&#xD;
      code, employment status, highest educational attainment, current topical eye medications,&#xD;
      Past Ocular History, Past Medical History&#xD;
&#xD;
      Recruitment for participation in the study will be performed during glaucoma clinic&#xD;
      registration Consent will be conducted by a member of the research team who is not directly&#xD;
      involved in the participant's clinical care Pre-intervention glaucoma knowledge questionnaire&#xD;
      (NEHEP glaucoma knowledge questionnaire) will be given to participants, to be completed on&#xD;
      dedicated clinic tablet device.&#xD;
&#xD;
      Post-intervention glaucoma knowledge questionnaire (NEHEP glaucoma knowledge questionnaire)&#xD;
      will be given to participants, to be completed on dedicated clinic tablet device.&#xD;
&#xD;
      Rate of missed glaucoma follow-up appointments before and 6 months after application use will&#xD;
      be collected from the electronic medical record.&#xD;
&#xD;
      Rate of medication adherence before and 6 months after application use will be collected from&#xD;
      the electronic medical record.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Questionnaire Scores</measure>
    <time_frame>From date of intervention to date of post-intervention NEHEP glaucoma knowledge test, assessed up to 2 months</time_frame>
    <description>Scores of pre- and post-intervention NEHEP glaucoma knowledge questionnaires will be compared</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Follow Up Adherence</measure>
    <time_frame>Before and 6 months after intervention</time_frame>
    <description>Attendance rate at glaucoma follow-ups will be collected from electronic medical record</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Medication Adherence</measure>
    <time_frame>Before and 6 months after intervention</time_frame>
    <description>Self-reported adherence to glaucoma medications will be collected from electronic medical record</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>EyeCU App</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augmented reality mobile application called &quot;EyeCU&quot; which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EyeCU Mobile Application</intervention_name>
    <description>Augmented reality glaucoma education mobile phone application</description>
    <arm_group_label>EyeCU App</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with a clinical diagnosis of glaucoma on medical therapy for at least 4 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with optic neuropathies unrelated to glaucoma&#xD;
&#xD;
          -  Patients with VA 20/100 or worse in both eyes&#xD;
&#xD;
          -  Visual defects involving fixation in both eyes&#xD;
&#xD;
          -  Patients with symptoms impairing ability to operate a smartphone during visit&#xD;
             including diplopia, motor difficulties, cognitive impairment, illiteracy&#xD;
&#xD;
          -  Patients who are unable to read or understand English or Spanish&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ernest Yoon, MD</last_name>
    <phone>7185185300</phone>
    <email>eyoon@bronxleb.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>BronxCare Health System</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest V Yoon, MD</last_name>
      <email>eyoon@bronxleb.org</email>
    </contact>
    <investigator>
      <last_name>Shlomit Sandler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Truong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Onelys Carrasquillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline Guzman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olanrewaju Akande</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen V Lau, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 3, 2021</last_update_submitted>
  <last_update_submitted_qc>July 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bronx-Lebanon Hospital Center Health Care System</investigator_affiliation>
    <investigator_full_name>Dr. Stephen Lau</investigator_full_name>
    <investigator_title>Ophthalmology Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

